Search - tctmd.com

Displaying 1 - 20 of 90

Sort: Relevancy | Date

Presentation AHA 2017

Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial

Presenter: Andre Lamy

November 15, 2017

Presentation AHA 2017

The POISE-2 PCI Substudy

Presenter: Michelle M. Graham

November 14, 2017

Presentation AHA 2017

Subgroup Analysis from the RE-DUAL PCI Trial

Presenter: Jonas Oldgren

November 14, 2017

Presentation AHA 2017

One-Year Outcomes: Prasugrel vs Ticagrelor in AMI Treated With PPCI PRAGUE-18 Study

Presenter: Zuzana Motovska

November 11, 2017

Presentation Cardiovascular Interventions 2017

DAPT Duration After Stenting: An Updated Appraisal

Presenter: Dean J. Kereiakes

November 09, 2017

Presentation TCT 2017

SENIOR and Shorter DAPT Studies: Highlights Summary

Presenter: Martin B. Leon, Marco Valgimigli, Olivier Varenne

November 01, 2017

Presentation TCT 2017

COMPASS Trial: Topline Findings and Practice Implications

Presenter: Robert A. Harrington, Evan A. Stein, Michelle O'Donoghue

November 01, 2017

Presentation TCT 2017

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Pascal Vranckx

November 01, 2017

Presentation TCT 2017

FOURIER Trial: Topline Findings and Practice Implications

Presenter: Robert A. Harrington, Evan A. Stein, Wolfgang Koenig

November 01, 2017

Presentation TCT 2017

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Renato D. Lopes

November 01, 2017

Presentation TCT 2017

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

When Bleeding Occurs on Warfarin or NOAC: Reversal Strategies

Presenter: Robert A. Harrington, Kurt Huber, Michael D. Ezekowitz

November 01, 2017

Presentation TCT 2017

When and Which Antiplatelet Agent Should Be Dropped When Using Oral Anticoagulant Therapy?

Presenter: Robert A. Harrington, Kurt Huber, Roxana Mehran

November 01, 2017

Presentation TCT 2017

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: Robert A. Harrington, Kurt Huber, Michelle O'Donoghue

November 01, 2017

Presentation TCT 2017

Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More

Presenter: Robert A. Harrington, Kurt Huber, Didier Carrié

November 01, 2017

Presentation TCT 2017

What Is (and Is Not) Known About DAPT Decisions in Patients on Chronic Oral Anticoagulants

Presenter: Robert A. Harrington, Kurt Huber, Freek W.A. Verheugt

November 01, 2017

Presentation TCT 2017

Optimizing the Acute and Chronic Use of Antiplatelet and Antithrombotic Agents (and Their Combination): 2017 Update

Presenter: Debabrata Mukherjee, E. Murat Tuzcu, Dimitrios Alexopoulos

November 01, 2017

Presentation TCT 2017

REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS

Presenter: Robert A. Harrington, Gregg W. Stone, Harry Suryapranata

November 01, 2017

Presentation TCT 2017

DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI

Presenter: Robert A. Harrington, Gregg W. Stone, Elvin Kedhi

November 01, 2017

Advertisement

Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial

The POISE-2 PCI Substudy

Subgroup Analysis from the RE-DUAL PCI Trial

One-Year Outcomes: Prasugrel vs Ticagrelor in AMI Treated With PPCI PRAGUE-18 Study

DAPT Duration After Stenting: An Updated Appraisal

SENIOR and Shorter DAPT Studies: Highlights Summary

COMPASS Trial: Topline Findings and Practice Implications

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

FOURIER Trial: Topline Findings and Practice Implications

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

When Bleeding Occurs on Warfarin or NOAC: Reversal Strategies

When and Which Antiplatelet Agent Should Be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More

What Is (and Is Not) Known About DAPT Decisions in Patients on Chronic Oral Anticoagulants

Optimizing the Acute and Chronic Use of Antiplatelet and Antithrombotic Agents (and Their Combination): 2017 Update

REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS

DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content